

## Supplementary table

Table 1. Baseline characteristics of 149 BEPAS patients excluded from study cohort due to missing radiographic data.

	<b>BEPAS patients excluded from current study (n=149)</b>	<b>BEPAS patients in current study cohort* (n=312)</b>	P-value <sup>□</sup>
Age at start study, years (mean±SD)	52.4±12.0	53.7±12.5	0.921
Age at disease onset, years (mean±SD)	41.4±12.7	41.3±15.3	0.945
Disease duration, years (mean±SD)	8.4±8.6	8.3±9.7	0.915
Female sex, n (%)	59 (39.6%)	140 (44.9%)	0.260
HLA-B27 positive <sup>○</sup> , n (%)	3/25 (12.0%)	24/136 (17.6%)	0.065
IBP <sup>◆</sup> , n (%)	12 (8.1%)	58 (18.6%)	0.003
Positive family history, n (%)	69 (46.3%)	157 (50.3%)	0.612
Psoriasis <40 years, n (%)	94 (62.3%)	193 (61.9%)	0.396
Peripheral arthritis, n (%)	86 (57.0%)	102 (32.7%)	<0.0001
Dactylitis, n (%)	18 (11.9%)	45 (14.4%)	0.605
Heel enthesitis, n (%)	29 (19.2%)	82 (26.3%)	0.102
Uveitis, n (%)	7 (5.3%)	15 (4.8%)	0.930
IBD, n (%)	2 (1.3%)	2 (0.6%)	0.458
Good response to NSAIDs, n (%)	74 (49.0%)	142 (45.5%)	0.241
Elevated ESR/CRP, n (%)	25 (16.6%)	50 (16.0%)	0.861
CRP, mg/L (mean±SD)	5.3±8.0	6.1±11.0	0.428

\* Patients included in the BEPAS cohort with radiographic imaging available. Data in this column I equal to that in table 1

□ Between PsA and all (axial and peripheral) SpA patients

○ HLA-B27; Human Leukocyte Antigen B27 typing was missing in 126 of the excluded patients and in 176 of the patients in current BEPAS study cohort.

◆ IBP; inflammatory back pain according to ASAS definition